Active Not RecruitingNot applicableNCT04691297

Digitally Enhanced Smoking Cessation for High Risk Smokers

This is a research study, is testing a program to improve lung health through smoking cessation and providing education around lung screening. In this research study involves Studying the Enhanced Smoking Cessation Approaches to Promote Empowerment (ESCAPE) program compared to usual care. The ESCAPE program was developed help women with HIV quit smoking. Women in the ESCAPE program quit smoking and stayed quit for longer (up to 3 months). For this study, investigators have added a lung screening to the ESCAPE program and want to test if this will improve lung health through increasing quit rates and lung screening. .

Checked against the public recordLast updated Dec 19, 2025 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhaseNot applicable
U.S. locations2
SponsorDana-Farber Cancer Institute
01
Study overview

What this study is about

Purpose
Prevention
Study type
Interventional
Phase
Not applicable
Sponsor
Dana-Farber Cancer Institute
Interventions being studied
Other: Escape; Other: Standard Care
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * 55 to 77 years of age * No previous history of lung cancer * ECOG performance status \< 2 * ≥ 30 pack year smoking history * Smoke ≥ 5 cigarettes/day * Own a mobile phone with access to a video call application * Has a primary care provider (PCP) * Provide contact information for the PCP * Active health insurance * Has not had LDCT screening * English speaking * Can complete an interview Exclusion Criteria: * Hospitalization for severe mental illness within the last year. * The following special populations will not be included * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Brigham and Women's HospitalBoston, Massachusetts
  • Dana Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 19, 2025. Always confirm current availability with the study team.

View original record ↗